Breaking News Instant updates and real-time market news.

2020-12-04 12:47:05 NVS Novartis $91.29 / +1.06 (+1.17%) , INCY Incyte $82.92 / +0.25 (+0.30%) 12:47 12/04/20 12/04 12:47 12/04/20 12:47	Novartis announces REACH3 trial of Jakavi reaches primary endpoint Detailed results from the pivotal Phase III REACH3 study demonstrate Jakavi significantly improved outcomes across a range of efficacy measures in patients with steroid-refractory/dependent chronic graft-versus-host disease, or GvHD, compared to best available therapy, Novartis (NVS) announced. The results of REACH3, which the company calls "the first successful, randomized Phase III trial in chronic GvHD," were presented today during the 62nd American Society of Hematology Annual Meeting & Exposition, or ASH. REACH3 is jointly sponsored by Novartis and Incyte (INCY). In REACH3, patients treated with Jakavi achieved significantly greater overall response rate compared to BAT at Week 24, the primary endpoint of the study. Jakavi also demonstrated statistically significant and clinically meaningful improvements in key secondary endpoints, the company said. David Feltquate, Head Hematology Development Unit, Novartis, added: "Jakavi is the first treatment to demonstrate efficacy in a large-scale randomized clinical trial in steroid-refractory/dependent chronic GvHD, and with these meaningful data we look forward to advancing discussions with regulatory authorities." NVS Novartis $91.29 / +1.06 (+1.17%) INCY Incyte $82.92 / +0.25 (+0.30%)	05 Dec 08 Dec 15 Dec
NVS INCY NVS Novartis $91.29 / +1.06 (+1.17%) 12/03/20 Argus Novartis price target raised to $112 from $100 at Argus 11/25/20 UBS Novartis price target raised to CHF 99 from CHF 98 at UBS 11/10/20 JPMorgan Novartis price target raised to CHF 85 from CHF 82 at JPMorgan 10/26/20 JMP Securities Kura Oncology price target raised to $33 from $22 at JMP Securities INCY Incyte $82.92 / +0.25 (+0.30%) 11/06/20 RBC Capital Incyte price target lowered to $86 from $96 at RBC Capital 09/18/20 Piper Sandler Piper Sandler lays out next potential takeover targets in oncology 09/14/20 Mizuho Oncology 'fertile ground for M&A activity,' says Mizuho 08/05/20 Mizuho Incyte price target raised to $95 from $79 at Mizuho

2020-12-04 12:47:05

NVS

Novartis

$91.29 / +1.06 (+1.17%)

, INCY

Incyte

$82.92 / +0.25 (+0.30%)

12:47

12/04/20

12/04

12:47

12/04/20

12:47

Novartis announces REACH3 trial of Jakavi reaches primary endpoint

Detailed results from the pivotal Phase III REACH3 study demonstrate Jakavi significantly improved outcomes across a range of efficacy measures in patients with steroid-refractory/dependent chronic graft-versus-host disease, or GvHD, compared to best available therapy, Novartis (NVS) announced. The results of REACH3, which the company calls "the first successful, randomized Phase III trial in chronic GvHD," were presented today during the 62nd American Society of Hematology Annual Meeting & Exposition, or ASH. REACH3 is jointly sponsored by Novartis and Incyte (INCY). In REACH3, patients treated with Jakavi achieved significantly greater overall response rate compared to BAT at Week 24, the primary endpoint of the study. Jakavi also demonstrated statistically significant and clinically meaningful improvements in key secondary endpoints, the company said. David Feltquate, Head Hematology Development Unit, Novartis, added: "Jakavi is the first treatment to demonstrate efficacy in a large-scale randomized clinical trial in steroid-refractory/dependent chronic GvHD, and with these meaningful data we look forward to advancing discussions with regulatory authorities."

NVS

Novartis

$91.29 / +1.06 (+1.17%)

INCY

Incyte

$82.92 / +0.25 (+0.30%)

05
Dec
08
Dec
15
Dec

NVS
INCY

NVS Novartis

$91.29 / +1.06 (+1.17%)

12/03/20 Argus: Novartis price target raised to $112 from $100 at Argus

11/25/20 UBS: Novartis price target raised to CHF 99 from CHF 98 at UBS

11/10/20 JPMorgan: Novartis price target raised to CHF 85 from CHF 82 at JPMorgan

10/26/20 JMP Securities: Kura Oncology price target raised to $33 from $22 at JMP Securities

INCY Incyte

$82.92 / +0.25 (+0.30%)

11/06/20 RBC Capital: Incyte price target lowered to $86 from $96 at RBC Capital

09/18/20 Piper Sandler: Piper Sandler lays out next potential takeover targets in oncology

09/14/20 Mizuho: Oncology 'fertile ground for M&A activity,' says Mizuho

08/05/20 Mizuho: Incyte price target raised to $95 from $79 at Mizuho

TODAY'S FREE FLY STORIES

Downgrade	Barclays downgraded to Neutral from Buy at Redburn » 05:11 01/27/21 01/27 05:11 01/27/21 05:11 BCS Barclays $7.60 / +0.075 (+1.00%) Redburn analyst Fahed… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options BCS Barclays $7.60 / +0.075 (+1.00%) 01/04/21 Penn National CFO David Williams steps down, Felicia Hendrix to succeed 12/15/20 ECB asks banks to refrain from or limit dividends until September 2021 12/15/20 ECB asks banks to refrain from or limit dividends until September 2021 12/04/20 Full House Resorts appoints Michael Hartmeier to board of directors BCS Barclays $7.60 / +0.075 (+1.00%) 01/18/21 Exane BNP Paribas Barclays upgraded to Outperform from Neutral at Exane BNP Paribas 01/15/21 JPMorgan Barclays price target raised to 180 GBp from 160 GBp at JPMorgan 01/11/21 Deutsche Bank Barclays price target raised to 180 GBp from 165 GBp at Deutsche Bank 01/11/21 UBS Barclays price target raised to 180 GBp from 140 GBp at UBS BCS Barclays $7.60 / +0.075 (+1.00%) 10/23/20 Barclays reports Q3 group profit before tax GBP 1.1B vs. GBP 0.2B last year 10/13/20 Fly Intel: What to watch in next round of big banks' earnings reports 07/29/20 Barclays reports 1H EPS 3.9p, revenue GBP11.62B, pretax profit GBP1.27B BCS Barclays $7.60 / +0.075 (+1.00%) 12/16/20 Barclays mulls raising bonus pool for traders by roughly 10%, Bloomberg says 10/01/20 Goldman Sachs to buy GM credit-card business for about $2.5B, WSJ reports 09/30/20 Barclays names Venkatakrishnan global head of markets, Bloomberg reports 09/15/20 Apple ends card partnership with Barclays, Bloomberg reports BCS Barclays $7.60 / +0.075 (+1.00%) 10/23/20 Fly Intel: Wall Street's top stories for Friday 10/23/20 Fly Intel: Wall Street's top stories at midday 10/01/20 Fly Intel: Wall Street's top stories for Thursday 09/11/20 The Intersection: Crypto and Wall Street This Week 03/25/21 REITwise 2021 Virtual Conference BCS Barclays $7.60 / +0.075 (+1.00%) 12/16/20 Barclays call volume above normal and directionally bullish 12/14/20 Unusual call flow in option market yesterday 12/11/20 Short-term premium buyer in Barclays 12/11/20 Unusually active option classes on open December 11th
Downgrade	Lloyds Banking downgraded to Sell from Neutral at Redburn » 05:11 01/27/21 01/27 05:11 01/27/21 05:11 LYG Lloyds Banking $1.86 / +0.02 (+1.09%) Redburn analyst Fahed… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings LYG Lloyds Banking $1.86 / +0.02 (+1.09%) 12/15/20 ECB asks banks to refrain from or limit dividends until September 2021 12/15/20 ECB asks banks to refrain from or limit dividends until September 2021 12/01/20 Credit Suisse proposes to name Lloyds CEO Horta-Osorio as chairman 10/29/20 Lloyds Banking sees NIM 'broadly stable' in Q4 LYG Lloyds Banking $1.86 / +0.02 (+1.09%) 01/11/21 Deutsche Bank Lloyds Banking price target raised to 38 GBp from 35 GBp at Deutsche Bank 01/11/21 Investec Lloyds Banking downgraded to Hold from Buy at Investec 12/11/20 Keefe Bruyette Lloyds Banking downgraded to Underperform from Outperform at Keefe Bruyette 12/04/20 BofA Lloyds Banking downgraded to Underperform from Neutral at BofA LYG Lloyds Banking $1.86 / +0.02 (+1.09%) 10/29/20 Lloyds Banking reports 9 months EPS 0.5p vs. 2.2p last year 07/30/20 Lloyds Banking reports 1H EPS (0.3p) vs. 2.7p last year
Downgrade	NatWest Group downgraded to Neutral from Buy at Redburn » 05:11 01/27/21 01/27 05:11 01/27/21 05:11 RBSPF NatWest Group $0.00 / + (+0.00%) Redburn analyst Fahed… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research RBSPF NatWest Group $0.00 / + (+0.00%) 01/18/21 Societe Generale NatWest Group upgraded to Buy from Hold at Societe Generale 01/18/21 Exane BNP Paribas NatWest Group downgraded to Underperform from Neutral at Exane BNP Paribas 12/11/20 JPMorgan NatWest Group downgraded to Neutral from Overweight at JPMorgan 11/25/20 Investec NatWest Group downgraded to Sell from Hold at Investec
Hot Stocks	Dada Group, Ferrero enter pact to create on-demand retail model for snacks » 05:11 01/27/21 01/27 05:11 01/27/21 05:11 DADA Dada Nexus $44.97 / +0.45 (+1.01%) Dada Group and Ferrero, a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options DADA Dada Nexus $44.97 / +0.45 (+1.01%) 01/25/21 Dada Nexus works with retailers to provide delivery service in Shijiazhuang 01/15/21 Dada Nexus announces JD Daojia partners with over 20 regional supermarkets 01/12/21 Aurora Mobile partners with Dada Now on user experience, account security 12/21/20 Dada Nexus, Unilever announce new strategic partnership DADA Dada Nexus $44.97 / +0.45 (+1.01%) 01/18/21 CICC Dada Nexus initiated with an Outperform at CICC 01/07/21 KeyBanc Dada Nexus initiated with an Overweight at KeyBanc 12/08/20 Fly Intel: Top five analyst downgrades 12/08/20 Morgan Stanley Dada Nexus downgraded to Equal Weight on competition risk at Morgan Stanley DADA Dada Nexus $44.97 / +0.45 (+1.01%) 11/19/20 Dada Nexus sees Q4 revenue RMB2B-RMB2.1B 11/19/20 Dada Nexus reports Q3 adjusted EPS RMB0.36 vs RMB1.71 last year 08/24/20 Dada Nexus sees Q3 revenue RMB 1.28B-1.34B, up 82% to 91% from last year 08/24/20 Dada Nexus reports Q2 EPS (11c), one estimate (18c) 03 Dec 05 Jun DADA Dada Nexus $44.97 / +0.45 (+1.01%) 11/30/20 Fly Intel: After-Hours Movers DADA Dada Nexus $44.97 / +0.45 (+1.01%) 12/23/20 new option listings and one option delisting on December 23rd
Downgrade	AP Moller Maersk downgraded to Neutral from Outperform at Exane BNP Paribas » 05:10 01/27/21 01/27 05:10 01/27/21 05:10 AMKBY AP Moller Maersk $0.00 / + (+0.00%) Exane BNP Paribas analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals AMKBY AP Moller Maersk $0.00 / + (+0.00%) 10/06/20 AP Moller Maersk awarded $173.05M Transportation Command contract modification AMKBY AP Moller Maersk $0.00 / + (+0.00%) 01/14/21 Deutsche Bank AP Moller Maersk price target raised to DKK 20,000 at Deutsche Bank 01/14/21 Morgan Stanley AP Moller Maersk price target raised to DKK 17,000 from DKK 16,800 01/12/21 JPMorgan AP Moller Maersk price target raised to DKK 16,982 from DKK 15,121 at JPMorgan 01/12/21 Berenberg AP Moller Maersk upgraded to Buy from Sell at Berenberg AMKBY AP Moller Maersk $0.00 / + (+0.00%) 11/17/20 Maersk raises fiscal 2020 EBITDA guidance to $8B-$8.5B 11/17/20 Maersk raises fiscal 2020 EBITDA guidance to $8B-$8.5B from $7.5B-$8B AMKBY AP Moller Maersk $0.00 / + (+0.00%) 09/18/20 Maersk undertakes reorganization, may cut nearly a third of headcount, WSJ says 09/01/20 Maersk plans major overhaul impacting thousands of jobs, Bloomberg reports

Downgrade	BioGaia downgraded to Hold from Buy at Danske Bank » 05:09 01/27/21 01/27 05:09 01/27/21 05:09 BIOGY BioGaia $0.00 / + (+0.00%) Danske Bank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Hot Stocks	Dr. Reddy's terminates Avigan Trial Study conducted in Kuwait » 05:07 01/27/21 01/27 05:07 01/27/21 05:07 RDY Dr. Reddy's $68.60 / -0.7499 (-1.08%) , APLIF Appili Therapeutics $0.00 / + (+0.00%) Dr. Reddy's (RDY)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research On The Fly Events RDY APLIF RDY Dr. Reddy's $68.60 / -0.7499 (-1.08%) 01/15/21 Dr. Reddy's receives approval to conduct Phase 3 trial for Sputnik V vaccine 01/11/21 Dr. Reddy's says DSMB recommends continuation of Phase 2 trial of Sputnik V 01/11/21 Dr. Reddy's announces launch of Febuxostat tablets in U.S. 12/22/20 Dr. Reddy's Canada files application for Reeqonos Tablets under interim order APLIF Appili Therapeutics $0.00 / + (+0.00%) 12/02/20 Appili Therapeutics doses first participant in Avigan trial 11/24/20 Appili Therapeutics gets clearance from Health Canada on Covid study 10/20/20 Appili Therapeutics enrolls, doses first cluster of patients in CONTROL trial RDY APLIF RDY Dr. Reddy's $68.60 / -0.7499 (-1.08%) 09/18/20 Investec Dr. Reddy's upgraded to Hold from Sell at Investec 09/03/20 Oppenheimer Opco 'more skeptical' on Amarin patent win after 20 minute court hearing 09/02/20 Goldman Sachs Oral arguments incrementally negative for Amarin, says Goldman Sachs 08/10/20 Oppenheimer Amarin Perform rating affirmed at Oppenheimer after FDA approves Vascepa generic APLIF Appili Therapeutics $0.00 / + (+0.00%) 09/02/20 Industrial Alliance Appili Therapeutics initiated with a Buy at Industrial Alliance RDY RDY Dr. Reddy's $68.60 / -0.7499 (-1.08%) 09/02/20 Amarin slides after Vascepa patent appeal hearing ends 01/29/21 Dr. Reddy's - RDY
Upgrade	Avantium upgraded to Hold from Reduce at Kepler Cheuvreux » 05:06 01/27/21 01/27 05:06 01/27/21 05:06 AVTXF Avantium $0.00 / + (+0.00%) Kepler Cheuvreux analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Downgrade	EDF downgraded to Reduce from Add at AlphaValue » 05:05 01/27/21 01/27 05:05 01/27/21 05:05 ECIFY EDF $0.00 / + (+0.00%) AlphaValue downgraded EDF… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research ECIFY EDF $0.00 / + (+0.00%) 01/12/21 Kepler Cheuvreux EDF upgraded to Buy from Hold at Kepler Cheuvreux 01/07/21 JPMorgan EDF price target raised to EUR 18.50 from EUR 15.50 at JPMorgan 12/03/20 Bernstein EDF upgraded to Outperform from Market Perform at Bernstein 12/02/20 Barclays EDF price target raised to EUR 16 from EUR 12.50 at Barclays
Initiation	Safehold initiated with a Buy at Goldman Sachs » 04:59 01/27/21 01/27 04:59 01/27/21 04:59 SAFE Safehold $77.29 / -0.45 (-0.58%) Goldman Sachs analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research Earnings Syndicate SAFE Safehold $77.29 / -0.45 (-0.58%) 11/12/20 Mizuho Safehold price target raised to $75 from $70 at Mizuho 10/23/20 Mizuho Safehold price target raised to $70 from $56 at Mizuho 07/27/20 Mizuho Safehold upgraded to Buy from Neutral at Mizuho 07/27/20 Mizuho Safehold upgraded to Buy from Neutral at Mizuho SAFE Safehold $77.29 / -0.45 (-0.58%) 10/22/20 Safehold reports Q3 EPS 28c, consensus 28c 11 Nov 18 Mar

Recommendations	Benefitfocus price target lowered to $20 from $29 at Piper Sandler » 04:57 01/27/21 01/27 04:57 01/27/21 04:57 BNFT Benefitfocus $13.49 / -0.41 (-2.95%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings BNFT Benefitfocus $13.49 / -0.41 (-2.95%) 11/02/20 Benefitfocus appoints John Thomas as Chief Data Officer 09/08/20 Benefitfocus appoints Robin Kirby as Chief Human Resources Officer 08/24/20 Benefitfocus CEO Raymond August steps down, Stephen Swad succeeds BNFT Benefitfocus $13.49 / -0.41 (-2.95%) 01/25/21 Raymond James Benefitfocus did not bid on South Carolina contract, says Raymond James 01/25/21 Raymond James South Carolina award 'a lost opportunity' for Benefitfocus, says Raymond James 01/21/21 Raymond James Benefitfocus downgraded at Raymond James on 'aggressive' consensus estimates 01/21/21 Raymond James Benefitfocus downgraded to Market Perform from Outperform at Raymond James BNFT Benefitfocus $13.49 / -0.41 (-2.95%) 08/24/20 Benefitfocus backs FY20 EPS view (59c)-(44c), consensus (49c) 08/24/20 Benefitfocus backs Q3 EPS view (21c)-(12c), consensus (14c) 08/05/20 Benefitfocus sees FY20 EPS (59c)-(44c), consensus (50c) 08/05/20 Benefitfocus sees Q3 EPS (21c)-(12c), consensus (17c)
Downgrade	Aurizon downgraded to Sell from Buy at Goldman Sachs » 04:55 01/27/21 01/27 04:55 01/27/21 04:55 QRNNF Aurizon $0.00 / + (+0.00%) Goldman Sachs analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research QRNNF Aurizon $0.00 / + (+0.00%) 03/31/20 Goldman Sachs Aurizon upgraded to Buy from Sell at Goldman Sachs
Conference/Events	Ardelyx participates in a conference call with Cantor Fitzgerald » 04:55 01/27/21 01/27 04:55 01/27/21 04:55 ARDX Ardelyx $7.33 / -0.36 (-4.68%) Biopharma Analyst Chen… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events ARDX Ardelyx $7.33 / -0.36 (-4.68%) 09/15/20 Ardelyx annonces FDA accepted NDA of Tenapanor ARDX Ardelyx $7.33 / -0.36 (-4.68%) 01/21/21 Piper Sandler Ardelyx remains a top pick into April PDUFA at Piper Sandler 01/05/21 Cantor Fitzgerald Ardelyx initiated with an Overweight at Cantor Fitzgerald 12/11/20 SVB Leerink Ardelyx price target raised to $14 from $11 at SVB Leerink 10/20/20 Citi Ardelyx transferred with Buy rating, $13 target at Citi ARDX Ardelyx $7.33 / -0.36 (-4.68%) 11/05/20 Ardelyx reports Q3 EPS (20c), consensus (28c) 08/06/20 Ardelyx reports Q2 EPS (28c), consensus (26c) ARDX Ardelyx $7.33 / -0.36 (-4.68%) 01/06/21 Fly Intel: Pre-market Movers 12/11/20 Fly Intel: Wall Street's top stories for Friday 12/11/20 Fly Intel: Wall Street's top stories at midday 03/01/21 41st Annual Healthcare Virtual Conference 11:00 Today Ardelyx - ARDX 04/29/21 PDUFA Date
Conference/Events	Midwest Energy Emissions to host conference call » 04:55 01/27/21 01/27 04:55 01/27/21 04:55 MEEC Midwest Energy Emissions $0.00 / + (+0.00%) Management holds a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Earnings Events MEEC Midwest Energy Emissions $0.00 / + (+0.00%) 01/19/21 Midwest Energy Emissions reaches license agreement with North American utility 01/11/21 Midwest Energy Emissions announces agreement with major national utility 12/01/20 Midwest Energy Emissions, AEP sign agreement for non-exclusive license 10/19/20 Midwest Energy Emissions engages MZ Group to lead investor relations MEEC Midwest Energy Emissions $0.00 / + (+0.00%) 11/24/20 Midwest Energy Emissions reports Q3 EPS (1c) vs. (1c) last year 11:30 Today Midwest Energy Emissions - MEEC
Conference/Events	Zymeworks to host conference call » 04:55 01/27/21 01/27 04:55 01/27/21 04:55 ZYME Zymeworks $46.27 / -2.16 (-4.46%) Conference call to … Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events ZYME Zymeworks $46.27 / -2.16 (-4.46%) 01/15/21 Zymeworks announces new, updated zanidatamab data at ASCO 12/01/20 Zymeworks expands zanidatamab trial in HER2 in amplified biliary tract cancer 11/30/20 Zymeworks gets FDA breakthrough therapy designation for zanidatamab 11/19/20 Zymeworks receives orphan drug designation for zanidatamab ZYME Zymeworks $46.27 / -2.16 (-4.46%) 01/25/21 Citi Zymeworks downgraded to Neutral ahead of initial ZW49 data at Citi 01/25/21 Citi Zymeworks downgraded to Neutral from Buy at Citi 01/12/21 SVB Leerink Zymeworks price target raised to $66 from $45 at SVB Leerink 01/12/21 Wells Fargo Zymeworks price target raised to $71 from $58 at Wells Fargo ZYME Zymeworks $46.27 / -2.16 (-4.46%) 11/03/20 Zymeworks reports Q3 EPS ($1.43), consensus (67c) 08/05/20 Zymeworks reports Q2 EPS (77c), consensus (67c) 16:30 Today Zymeworks - ZYME

Conference/Events	Akebia management to meet virtually with Mizuho » 04:55 01/27/21 01/27 04:55 01/27/21 04:55 AKBA Akebia $3.77 / +0.06 (+1.62%) Virtual Meetings to be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 7 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options AKBA Akebia $3.77 / +0.06 (+1.62%) 11/16/20 Akebia reports manuscript on global Phase 3 INNO2VATE program rationale 10/23/20 Akebia down 1% to $3.24 after reporting additional data on vadadustat 10/23/20 Akebia trading resumes 10/23/20 Akebia CEO confident vadadustat has 'straightforward path to potential approval' AKBA Akebia $3.77 / +0.06 (+1.62%) 10/23/20 Piper Sandler Akebia rally justified as vadadustat has chance, says Piper Sandler 10/23/20 JPMorgan JPMorgan says Akebia's data 'do little' to restore confidence in NDD approval 09/04/20 RBC Capital Akebia price target lowered to $5 from $12 at RBC Capital 09/04/20 Stifel FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel AKBA Akebia $3.77 / +0.06 (+1.62%) 11/05/20 Akebia reports Q3 EPS (42c), consensus (17c) 08/10/20 Akebia reports Q2 EPS ($1.28), consensus (50c) 12 May AKBA Akebia $3.77 / +0.06 (+1.62%) 01/13/21 Researchers awarded funding to expand Akebia drug trial, UTHealth News says AKBA Akebia $3.77 / +0.06 (+1.62%) 09/03/20 Fly Intel: Wall Street's top stories for Thursday 09/03/20 Fly Intel: Wall Street's top stories at midday 09/03/20 Fly Intel: Pre-market Movers 08/10/20 Fly Intel: After-Hours Movers 00:00 Today Arcus Biosciences AKBA Akebia $3.77 / +0.06 (+1.62%) 10/12/20 Unusually active option classes on open October 12th
General news	January Fed Chair Press Conference to be released at 14:30 04:55 01/27/21 01/27 04:55 01/27/21 04:55
General news	Week of 1/22 MBA Mortgage Applications to be released at 07:00 04:55 01/27/21 01/27 04:55 01/27/21 04:55
General news	FOMC Announcement Federal Funds Rate to be reported at 14:00 » 04:55 01/27/21 01/27 04:55 01/27/21 04:55 January FOMC Announcement… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 8 minutes Get Free Trial
Conference/Events	Barnes & Noble Education management to meet virtually with Craig Hallum » 04:55 01/27/21 01/27 04:55 01/27/21 04:55 BNED Barnes & Noble Education $5.22 / -0.065 (-1.23%) Virtual Meeting to be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 8 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events BNED Barnes & Noble Education $5.22 / -0.065 (-1.23%) 12/29/20 Barnes & Noble Education rises 10.0% 12/29/20 Barnes & Noble Education rises 10.1% 12/21/20 Barnes & Noble Education enters merchandising partnership with Fanatics, Lids 10/12/20 Barnes & Noble College introduce custom-branded version of First Day Complete BNED Barnes & Noble Education $5.22 / -0.065 (-1.23%) 09/04/20 Fly Intel: Top five analyst upgrades 09/04/20 Craig-Hallum Barnes & Noble Education upgraded to Buy from Hold at Craig-Hallum 05/13/20 Needham CA schools online in fall negative for Barnes & Noble Education, says Needham 03/16/20 Craig-Hallum Barnes & Noble Education downgraded to Hold from Buy at Craig-Hallum BNED Barnes & Noble Education $5.22 / -0.065 (-1.23%) 12/08/20 Barnes & Noble Education reports Q2 EPS 15c, consensus (46c) 09/03/20 Barnes & Noble Education reports Q1 EPS (96c), two estimates (78c) BNED Barnes & Noble Education $5.22 / -0.065 (-1.23%) 12/29/20 Barnes & Noble Education CFO expects more cost cutting amid pandemic, WSJ says BNED Barnes & Noble Education $5.22 / -0.065 (-1.23%) 12/29/20 Fly Intel: Pre-market Movers 00:00 Today Barnes & Noble Education

Conference/Events	Earthstone Energy management to meet virtually with Roth Capital » 04:55 01/27/21 01/27 04:55 01/27/21 04:55 ESTE Earthstone Energy $5.34 / -0.24 (-4.30%) Virtual Meetings to be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events ESTE Earthstone Energy $5.34 / -0.24 (-4.30%) 12/18/20 Earthstone Energy rises 14.8% 12/18/20 Earthstone Energy to acquire IRM for $185.9M in cash, shares 11/04/20 Earthstone Energy sees FY20 CapEx $65M-$70M 08/05/20 Earthstone Energy expects to average 13,000 - 14,000 Boepd for full year ESTE Earthstone Energy $5.34 / -0.24 (-4.30%) 01/04/21 Northland Earthstone Energy named a Top Pick for 2021 at Northland 12/16/20 Wells Fargo Wells Fargo says Buy Marathon Oil, Sell Berry Petroleum 12/16/20 Wells Fargo Earthstone Energy upgraded to Overweight from Equal Weight at Wells Fargo 09/02/20 Alliance Global Partners Earthstone Energy assumed with a Buy at Alliance Global Partners ESTE Earthstone Energy $5.34 / -0.24 (-4.30%) 11/04/20 Earthstone Energy reports Q3 adjusted EPS (18c), consensus 8c 08/05/20 Earthstone Energy reports Q2 adjusted EPS 20c, consensus 10c 03/15/21 33rd Annual Roth Virtual Conference 00:00 Today Earthstone Energy
Conference/Events	Romeo Power management to meet virtually with BTIG » 04:55 01/27/21 01/27 04:55 01/27/21 04:55 RMO Romeo Power $20.16 / +1.66 (+8.97%) Virtual Meeting to be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News On The Fly Events Options RMO Romeo Power $20.16 / +1.66 (+8.97%) 01/13/21 Romeo Power rises 10.1% 01/04/21 HES, Romeo Power launch program to select fleet electrification partners 12/30/20 Romeo Power CEO calls current electrification rate forecasts 'really low' 12/29/20 Romeo Power and RMG Acquisition announce closing of business combination RMO Romeo Power $20.16 / +1.66 (+8.97%) 10/09/20 Workhorse seen as 'best fit' for $8.1B Post Office contract 00:00 Today Romeo Power RMO Romeo Power $20.16 / +1.66 (+8.97%) 12/30/20 Three new option listings and four option delistings on December 30th
Conference/Events	Aqua Metals hosts a conference call » 04:55 01/27/21 01/27 04:55 01/27/21 04:55 AQMS Aqua Metals $7.21 / +1.32 (+22.41%) President & CEO… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Events AQMS Aqua Metals $7.21 / +1.32 (+22.41%) 01/25/21 Aqua Metals, BASF establish global partnership 12/28/20 Aqua Metals completes V1.25L electrolyzer program on time, under budget 09/29/20 Aqua Metals receives additional $1.5M insurance payment 09/22/20 Aqua Metals announces intention to sell McCarran, Nevada plant AQMS Aqua Metals $7.21 / +1.32 (+22.41%) 03/12/20 Oppenheimer Aqua Metals price target lowered to $2 from $9 at Oppenheimer 14:00 Today Aqua Metals - AQMS
General news	Week of 1/22 MBA Mortgage Applications to be released at 07:00 04:55 01/27/21 01/27 04:55 01/27/21 04:55
Conference/Events	Newborn Acquisition Corp. management to meet virtually with Roth Capital » 04:55 01/27/21 01/27 04:55 01/27/21 04:55 NBAC Newborn Acquisition Corp. $21.70 / +4.64 (+27.20%) Virtual Meetings to be… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Events NBAC Newborn Acquisition Corp. $21.70 / +4.64 (+27.20%) 12/16/20 Nuvve Corporation, IoTecha partner on EV charging solution 11/19/20 Nuvve, Lion Electric announce vehicle-to-grid collaboration 11/12/20 Newborn Acquisition Corp., Nuvve sign merger pact to take Nuvve public 00:00 Today Newborn Acquisition Corp.

Events

Earnings calls, analyst events, roadshows and more

Today at 07:00

MBA Mortgage Applications: Composite Index W/W: 1/22/2021 Government Event
Today at 07:00

MBA Mortgage Applications: Purchase Index W/W: 1/22/2021 Government Event
Today at 07:00

MBA Mortgage Applications: Refinance Index W/W: 1/22/2021 Government Event
TXT
Today at 08:00

Textron - TXT Conference Calls
CLS
Today at 08:00

Celestica - CLS Conference Calls
MPX
Today at 08:00

Marine Products - MPX Conference Calls
NDAQ
Today at 08:00

Nasdaq - NDAQ Conference Calls
NAVI
Today at 08:00

Navient - NAVI Conference Calls
Today at 08:30

Durable Goods Orders--Core Capital Goods M/M: December 2020 Government Event
Today at 08:30

Durable Goods New Orders M/M: December 2020 Government Event

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	EZGO X EZGO EZGO Technologies IPO Managers: Priced at: $4.00 2.8M Shares CRKN X CRKN Crown Electrokinetics Secondary Managers: Roth Capital, National Securities, Colliers Priced at: $4.50 4.15M Shares LPCN X LPCN Lipocine Spot Secondary Managers: Raymond James Priced at: $1.75 14.3M Shares SEEL X SEEL Seelos Therapeutics Spot Secondary Managers: BTIG Priced at: $2.05 15.244M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	GRBK X GRBK Green Brick Secondary Managers: Barclays & Goldman Sachs Priced at: $20.95 6M Shares
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	ERF X ERF Enerplus Spot Secondary Managers: RBC Capital & BMO Capital $3.37 28.75M Shares
Tues	SHLS X SHLS Shoals Technologies IPO Managers: Goldman Sachs, JPMorgan, Guggenheim, UBS, Morgan Stanley, Barclays & Credit Suisse, Cowen, Oppenheimer $22.00-23.00 70M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CBIO X CBIO Catalyst Biosciences Spot Secondary Managers: Piper Sandler, Raymond James $5.75-6.00 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DZSI X DZSI DZS Spot Secondary Managers: Stifel, Needham & B. Riley Securities $14.00 - 14.50 4M Shares PLUG X PLUG Plug Power Spot Secondary Managers: Morgan Stanley $65.00-67.00 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PSNL X PSNL Personalis Spot Secondary Managers: Morgan Stanley, BofA, Citi & Cowen $38.00 - 40.00 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial QUMU X QUMU Qumu Spot Secondary Managers: Craig-Hallum $8.10 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	AGFY X AGFY Agrify IPO Managers: Maxim & Roth Capital $8.00-10.00 5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial OCDX X OCDX Ortho Clinical IPO Managers: JPMorgan, BofA, Goldman Sachs, Barclays & Morgan Stanley, Citi, Credit Suisse, UBS, Evercore ISI, Piper Sandler, ING Bank, Macquarie, Nomura, TCG Capital Markets, Drexel Hamilton, H.C. Wainwright, Ramirez, Seibert Williams $20.00-23.00 70M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VINP X VINP Vinci Partners Investments IPO Managers: JPMorgan, Goldman Sachs & BTG Pactual, Itau BBA, BofA, Credit Suisse, UBS $16.00-18.00 13.873M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial XM X XM Qualtrics IPO Managers: Morgan Stanley & JPMorgan, BofA, Barclays, Deutsche Bank, Goldman Sachs, HSBC, Citi, BMO Capital, Truist, Canaccord, Evercore ISI, JPMorgan, Oppenheimer, Piper Sandler, Raymond James, William Blair, Loop Capital, RMRZ, SEEL $27.00-29.00 50.4M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ZIM X ZIM ZIM Integrated IPO Managers: Citi, Goldman Sachs & Barclays, Jefferies, Clarksons Platou $16.00-19.00 17.5M Shares ASO X ASO Academy Sports Secondary Managers: Credit Suisse, JPMorgan, KKR & BofA $23.69 12M Shares CVAC X CVAC CureVac Secondary Managers: BofA, Jefferies & Evercore ISI, UBS, Guggenheim, Berenberg, Kempen & Co., $104.50 5M Shares SEER X SEER Seer Secondary Managers: JPMorgan, Morgan Stanley, BofA & Cowen $81.35 3.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SGRY X SGRY Surgery Partners Secondary Managers: JPMorgan & Jefferies, Barclays, KKR, Macquarie $31.30 6M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SRGA X SRGA Surgalign Secondary Managers: Piper Sandler, Cantor Fitzgerald & BTIG, Craig-Hallum, Lake Street $2.11 25M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	HMPT X HMPT Home Point Capital IPO Managers: Goldman Sachs, Wells Fargo, Morgan Stanley & UBS, Credit Suisse, JPMorgan, BofA, JMP Securities, Piper Sandler, Seelaus, SPC Capital, Wedbush, Zelman $19.00-21.00 12.5M Shares SEGR X SEGR Southeastern Grocers IPO Managers: BofA & Goldman Sachs, Deutsche Bank, BMO Capital, Truist, Wells Fargo $14.00-16.00 8.9M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TRIN X TRIN Trinity Capital IPO Managers: Keefe Bruyette, Wells Fargo & UBS, Janney Montgomery Scott, B. Riley Securities, Ladenburg, Compass Point $13.50-15.50 7.55M Shares CALT X CALT Calliditas Therapeutics Secondary Managers: Citi, Jefferies & Stifel, Kempen & Co.,, LifeSci Capital, Carnegie $31.20 4.5M Shares DCT X DCT Duck Creek Technologies Secondary Managers: Goldman Sachs, JPMorgan & BofA $52.85 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

View All Syndicate Announcements »

Novartis announces REACH3 trial of Jakavi reaches primary endpoint

TODAY'S FREE FLY STORIES

Get Full Fly Access